Breast cancer: biological characteristics in postmenopausal type 2 diabetic women. Identification of therapeutic targets.

E. Guastamacchia, F. Resta, A. Mangia, F. Schittulli, A. Ciampolillo, V. Triggiani, B. Licchelli, A. Paradiso, C. Sabbà, E. Tafaro

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

HYPOTHESIS: Epidemiological data have suggested a possible relationship between diabetes mellitus and cancer risk, particularly breast cancer. We set out to investigate the effect of diabetes mellitus on the expression of estrogen and progesteron receptors and on the proliferative activity of primary breast cancer. METHODS: We selected 77 diabetic women and 578 control patients all in post-menopause and diagnosed with primary breast cancer. All patients underwent surgical excision of the tumor and on the specimens were performed an assessment of estrogen receptor and progesteron receptor and proliferative activity assay by (3)H-Thymidine incorporation. RESULTS: Diabetic women showed a decreased proliferative activity, while having the same estrogen receptor and progesteron receptor status and mean cytoplasmic concentration of their receptors than control group. Insulin treated women had a lower proliferative activity than non-insulin treated ones. CONCLUSION: Hyperinsulinemia and hyperglicemia influence in negative way the proliferative activity of diabetic women, likely inducing the expression of transforming growth factor beta, despite the high serum levels of Insulin-like growth factor and estrogen.

Original languageEnglish
Pages (from-to)205-209
Number of pages5
JournalCurrent Drug Targets: Immune, Endocrine and Metabolic Disorders
Volume3
Issue number3
Publication statusPublished - Sep 2003

Fingerprint

Progesterone Receptors
Estrogen Receptors
Breast Neoplasms
Diabetes Mellitus
Postmenopause
Hyperinsulinism
Somatomedins
Therapeutics
Transforming Growth Factor beta
Thymidine
Neoplasms
Estrogens
Insulin
Control Groups
Serum

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Immunology and Allergy

Cite this

Breast cancer : biological characteristics in postmenopausal type 2 diabetic women. Identification of therapeutic targets. / Guastamacchia, E.; Resta, F.; Mangia, A.; Schittulli, F.; Ciampolillo, A.; Triggiani, V.; Licchelli, B.; Paradiso, A.; Sabbà, C.; Tafaro, E.

In: Current Drug Targets: Immune, Endocrine and Metabolic Disorders, Vol. 3, No. 3, 09.2003, p. 205-209.

Research output: Contribution to journalArticle

Guastamacchia, E, Resta, F, Mangia, A, Schittulli, F, Ciampolillo, A, Triggiani, V, Licchelli, B, Paradiso, A, Sabbà, C & Tafaro, E 2003, 'Breast cancer: biological characteristics in postmenopausal type 2 diabetic women. Identification of therapeutic targets.', Current Drug Targets: Immune, Endocrine and Metabolic Disorders, vol. 3, no. 3, pp. 205-209.
Guastamacchia, E. ; Resta, F. ; Mangia, A. ; Schittulli, F. ; Ciampolillo, A. ; Triggiani, V. ; Licchelli, B. ; Paradiso, A. ; Sabbà, C. ; Tafaro, E. / Breast cancer : biological characteristics in postmenopausal type 2 diabetic women. Identification of therapeutic targets. In: Current Drug Targets: Immune, Endocrine and Metabolic Disorders. 2003 ; Vol. 3, No. 3. pp. 205-209.
@article{a0a034c9a9b8414d8e70ef05453b3aed,
title = "Breast cancer: biological characteristics in postmenopausal type 2 diabetic women. Identification of therapeutic targets.",
abstract = "HYPOTHESIS: Epidemiological data have suggested a possible relationship between diabetes mellitus and cancer risk, particularly breast cancer. We set out to investigate the effect of diabetes mellitus on the expression of estrogen and progesteron receptors and on the proliferative activity of primary breast cancer. METHODS: We selected 77 diabetic women and 578 control patients all in post-menopause and diagnosed with primary breast cancer. All patients underwent surgical excision of the tumor and on the specimens were performed an assessment of estrogen receptor and progesteron receptor and proliferative activity assay by (3)H-Thymidine incorporation. RESULTS: Diabetic women showed a decreased proliferative activity, while having the same estrogen receptor and progesteron receptor status and mean cytoplasmic concentration of their receptors than control group. Insulin treated women had a lower proliferative activity than non-insulin treated ones. CONCLUSION: Hyperinsulinemia and hyperglicemia influence in negative way the proliferative activity of diabetic women, likely inducing the expression of transforming growth factor beta, despite the high serum levels of Insulin-like growth factor and estrogen.",
author = "E. Guastamacchia and F. Resta and A. Mangia and F. Schittulli and A. Ciampolillo and V. Triggiani and B. Licchelli and A. Paradiso and C. Sabb{\`a} and E. Tafaro",
year = "2003",
month = "9",
language = "English",
volume = "3",
pages = "205--209",
journal = "Current Drug Targets: Immune, Endocrine and Metabolic Disorders",
issn = "1568-0088",
publisher = "Bentham Science Publishers B.V.",
number = "3",

}

TY - JOUR

T1 - Breast cancer

T2 - biological characteristics in postmenopausal type 2 diabetic women. Identification of therapeutic targets.

AU - Guastamacchia, E.

AU - Resta, F.

AU - Mangia, A.

AU - Schittulli, F.

AU - Ciampolillo, A.

AU - Triggiani, V.

AU - Licchelli, B.

AU - Paradiso, A.

AU - Sabbà, C.

AU - Tafaro, E.

PY - 2003/9

Y1 - 2003/9

N2 - HYPOTHESIS: Epidemiological data have suggested a possible relationship between diabetes mellitus and cancer risk, particularly breast cancer. We set out to investigate the effect of diabetes mellitus on the expression of estrogen and progesteron receptors and on the proliferative activity of primary breast cancer. METHODS: We selected 77 diabetic women and 578 control patients all in post-menopause and diagnosed with primary breast cancer. All patients underwent surgical excision of the tumor and on the specimens were performed an assessment of estrogen receptor and progesteron receptor and proliferative activity assay by (3)H-Thymidine incorporation. RESULTS: Diabetic women showed a decreased proliferative activity, while having the same estrogen receptor and progesteron receptor status and mean cytoplasmic concentration of their receptors than control group. Insulin treated women had a lower proliferative activity than non-insulin treated ones. CONCLUSION: Hyperinsulinemia and hyperglicemia influence in negative way the proliferative activity of diabetic women, likely inducing the expression of transforming growth factor beta, despite the high serum levels of Insulin-like growth factor and estrogen.

AB - HYPOTHESIS: Epidemiological data have suggested a possible relationship between diabetes mellitus and cancer risk, particularly breast cancer. We set out to investigate the effect of diabetes mellitus on the expression of estrogen and progesteron receptors and on the proliferative activity of primary breast cancer. METHODS: We selected 77 diabetic women and 578 control patients all in post-menopause and diagnosed with primary breast cancer. All patients underwent surgical excision of the tumor and on the specimens were performed an assessment of estrogen receptor and progesteron receptor and proliferative activity assay by (3)H-Thymidine incorporation. RESULTS: Diabetic women showed a decreased proliferative activity, while having the same estrogen receptor and progesteron receptor status and mean cytoplasmic concentration of their receptors than control group. Insulin treated women had a lower proliferative activity than non-insulin treated ones. CONCLUSION: Hyperinsulinemia and hyperglicemia influence in negative way the proliferative activity of diabetic women, likely inducing the expression of transforming growth factor beta, despite the high serum levels of Insulin-like growth factor and estrogen.

UR - http://www.scopus.com/inward/record.url?scp=2442659101&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2442659101&partnerID=8YFLogxK

M3 - Article

C2 - 12871027

AN - SCOPUS:2442659101

VL - 3

SP - 205

EP - 209

JO - Current Drug Targets: Immune, Endocrine and Metabolic Disorders

JF - Current Drug Targets: Immune, Endocrine and Metabolic Disorders

SN - 1568-0088

IS - 3

ER -